Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems

Drug Development and Industrial Pharmacy

Volumn 39, Issue 9, 2013, Pages 1431-1438

  Kim, Gun Gook ^a   Poudel, Bijay K ^a   Marasini, Nirmal ^a   Lee, Dong Won ^a   Hiep, Tran Tuan ^a   Yang, Kwan Yeol ^a   Kim, Jong Oh ^a   Yong, Chul Soon ^a   Choi, Han Gon ^b  

^a Yeungnam University   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Bioavailability; Fenofibrate; SMEDDS; Solubility; Spray drying

Indexed keywords

DEXTRAN; DRUG CARRIER; FENOFIBRATE;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; INTESTINE ABSORPTION; IONIC STRENGTH; MALE; MELTING POINT; MICROEMULSION; NONHUMAN; PARTICLE SIZE; PH; POWDER; RAT; SOLID STATE; SOLUBILIZATION; SPRAY DRYING; X RAY DIFFRACTION;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CAPRYLATES; DEXTRANS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; EMULSIONS; FENOFIBRATE; GLYCERIDES; HALF-LIFE; HYPOLIPIDEMIC AGENTS; MALE; ORGANIC CHEMICALS; PHYSICOCHEMICAL PHENOMENA; POLYETHYLENE GLYCOLS; POLYMERS; PROPYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 84879766149     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.719903     Document Type: Article

References (31)

1. Adkins JC, Faulds D. (1997). Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs, 54:615-633. (Pubitemid 27464158)
2. Balfour JA, McTavish D, Heel RC. (1990). Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs, 40:260-290.
3. Genest J Jr, Nguyen NH, Theroux P, Davignon J, Cohn JS. (2000). Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. J Cardiovasc Pharmacol, 35:164-172. (Pubitemid 30032909)
4. Packard CJ. (1998). Overview of fenofibrate. Eur Heart J, 19 Suppl A:A62-A65. (Pubitemid 28112480)
5. Amidon GL, Lennern? H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
6. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennern? H, Hussain AS et al. (2004). Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm, 1:85-96.
7. Patel AR, Vavia PR. (2006). Effect of hydrophilic polymer on solubilization of fenofibrate by cyclodextrin complexation. J Incl Phenom Macro, 56:247-251.
8. Law D, Wang W, Schmitt EA, Qiu Y, Krill SL, Fort JJ. (2003). Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure. J Pharm Sci, 92:505-515. (Pubitemid 36258965)
9. Curtet B, Teillaud E, Reginault P, inventors. (1980.) Fournier Innovation et Synergie, assignee. Novel dosage form of fenofibrate. US patent 4: 895 726.
10. Pouton CW. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci, 29:278-287. (Pubitemid 44740131)
11. Rane SS, Anderson BD. (2008). What determines drug solubility in lipid vehicles: is it predictable? Adv Drug Deliv Rev, 60:638-656.
12. Cui SX, Nie SF, Li L, Wang CG, Pan WS, Sun JP. (2009). Preparation and evaluation of self-microemulsifying drug delivery system containing vinpocetine. Drug Dev Ind Pharm, 35:603-611.
13. Woo JS, Song YK, Hong JY, Lim SJ, Kim CK. (2008). Reduced foodeffect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur J Pharm Sci, 33:159-165.
14. Chang RK, Raghavan KS, Hussain MA. (1998). A study on gelatin capsule brittleness: moisture tranfer between the capsule shell and its content. J Pharm Sci, 87:556-558. (Pubitemid 28225618)
15. Nazzal S, Wang Y. (2001). Characterization of soft gelatin capsules by thermal analysis. Int J Pharm, 230:35-45. (Pubitemid 32973857)
16. Mei X, Etzler FM, Wang Z. (2006). Use of texture analysis to study hydrophilic solvent effects on the mechanical properties of hard gelatin capsules. Int J Pharm, 324:128-135. (Pubitemid 44528913)
17. Franceschinis E, Voinovich D, Grassi M, Perissutti B, Filipovic-Grcic J, Martinac A et al. (2005). Self-emulsifying pellets prepared by wet granulation in high-shear mixer: influence of formulation variables and preliminary study on the in vitro absorption. Int J Pharm, 291:87-97. (Pubitemid 40222000)
18. Choi HG, Lee BJ, Han JH, Lee MK, Park KM, Yong CS et al. (2001). Terfenadine-beta-Cyclodextrin inclusion complex with antihistaminic activity enhancement. Drug Dev Ind Pharm, 27:857-862. (Pubitemid 33029512)
19. Li DX, Oh YK, Lim SJ, Kim JO, Yang HJ, Sung JH et al. (2008). Novel gelatin microcapsule with bioavailability enhancement of ibuprofen using spray-drying technique. Int J Pharm, 355:277-284.
20. Society of Toxicology (SOT). (1999). Guiding principles in the use of animals in toxicology. Available from: http://www.toxicology.org/ai/fa/ guidingprinciples.pdf (Accessed 21 August 2011).
21. Hanafy A, Spahn-Langguth H, Vergnault G, Grenier P, Tubic Grozdanis M, Lenhardt T et al. (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev, 59:419-426. (Pubitemid 47260709)
22. Pradhan R, Lee DW, Choi HG, Yong CS, Kim JO. (2012). Fabrication of a uniformly sized fenofibrate microemulsion by membrane emulsification. J Microencapsul, doi:10.3109/02652048.2012.692403
23. Cole ET, CadD, Benameur H. (2008). Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. Adv Drug Deliv Rev, 60:747-756.
24. Prasad YV, Puthli SP, Eaimtrakarn S, Ishida M, Yoshikawa Y, Shibata N et al. (2003). Enhanced intestinal absorption of vancomycin with Labrasol and D-alpha-tocopheryl PEG 1000 succinate in rats. Int J Pharm, 250:181-190. (Pubitemid 35447948)
25. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G et al. (2004). Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm, 274:65-73. (Pubitemid 38457007)
26. Pouton C. (1985). Effects of the inclusion of a model drug on the performance of self-emulsifying formulations. J Pharm Pharmacol, 37:1P-4P.
27. Lawrence MJ, Rees GD. (2000). Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev, 45:89-121.
28. Balakrishnan P, Lee BJ, Oh DH, Kim JO, Hong MJ, Jee JP et al. (2009). Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm, 72:539-545.
29. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. (2005). Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm, 293:155-164. (Pubitemid 40381089)
30. Yan YD, Kim JA, Kwak MK, Yoo BK, Yong CS, Choi HG. (2011). Enhanced oral bioavailability of curcumin via a solid lipid-based self-emulsifying drug delivery system using a spray-drying technique. Biol Pharm Bull, 34:1179-1186.
31. Oh DH, Kang JH, Kim DW, Lee BJ, Kim JO, Yong CS et al. (2011). Comparison of solid self-microemulsifying drug delivery system (solid SMEDDS) prepared with hydrophilic and hydrophobic solid carrier. Int J Pharm, 420:412-418.